These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36787372)

  • 1. Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
    Boonpheng B; De Castro ICC; Ng YH; Blosser C; Bakthavatsalam R; Gimferrer I; Smith K; Leca N
    Clin Transplant; 2023 May; 37(5):e14936. PubMed ID: 36787372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived cell-free DNA predicted allograft rejection and severe microvascular inflammation in kidney transplant recipients.
    Kim HD; Bae H; Kang H; Lee H; Eum SH; Yang CW; Choi YJ; Chung BH; Oh EJ
    Front Immunol; 2024; 15():1433918. PubMed ID: 39044817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients.
    Mayer KA; Doberer K; Tillgren A; Viard T; Haindl S; Krivanec S; Reindl-Schwaighofer R; Eder M; Eskandary F; Casas S; Wahrmann M; Regele H; Böhmig GA
    Transpl Int; 2021 Sep; 34(9):1689-1702. PubMed ID: 34448270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a donor-derived cell-free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection.
    Steggerda JA; Pizzo H; Garrison J; Zhang X; Haas M; Kim IK; Jordan SC; Puliyanda DP
    Pediatr Transplant; 2022 Jun; 26(4):e14258. PubMed ID: 35340104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of donor-derived Cell-Free DNA in pediatric kidney transplant recipients: A single center study.
    Ranch D; Fei M; Kincade E; Piburn K; Hitchman K; Klein K
    Pediatr Transplant; 2024 Feb; 28(1):e14582. PubMed ID: 37550268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study.
    Halloran PF; Reeve J; Madill-Thomsen KS; Demko Z; Prewett A; Gauthier P; Billings P; Lawrence C; Lowe D; Hidalgo LG;
    Transplantation; 2023 Mar; 107(3):709-719. PubMed ID: 36190186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab for antibody-mediated rejection treatment in lung transplantation.
    January SE; Fester KA; Halverson LP; Witt CA; Byers DE; Vazquez-Guillamet R; Alexander-Brett J; Tague LK; Kreisel D; Gelman A; Puri V; Bahena RN; Takahashi T; Hachem RR; Kulkarni HS
    J Heart Lung Transplant; 2023 Oct; 42(10):1353-1357. PubMed ID: 37268051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Multi-Organ Transplants.
    Moeller CM; Oren D; Fernandez Valledor A; Rubinstein G; Lotan D; Mehlman Y; Slomovich S; Rahman S; Lee C; Baranowska J; Regan M; Elad B; DeFilippis EM; Hennecken C; Salazar R; Raikhelkar J; Clerkin KJ; Fried J; Lin E; Bae D; Oh KT; Latif F; Topkara VK; Naka Y; Takeda K; Majure D; Uriel N; Sayer G
    Clin Transplant; 2024 Oct; 38(10):e15479. PubMed ID: 39422086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study.
    Khush KK; Patel J; Pinney S; Kao A; Alharethi R; DePasquale E; Ewald G; Berman P; Kanwar M; Hiller D; Yee JP; Woodward RN; Hall S; Kobashigawa J
    Am J Transplant; 2019 Oct; 19(10):2889-2899. PubMed ID: 30835940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
    Pearl M; Weng PL; Chen L; Dokras A; Pizzo H; Garrison J; Butler C; Zhang J; Reed EF; Kim IK; Choi J; Haas M; Zhang X; Vo A; Chambers ET; Ettenger R; Jordan S; Puliyanda D
    Clin Transplant; 2022 Aug; 36(8):e14734. PubMed ID: 35657013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor-derived cell-free DNA (dd-cfDNA) for detection of allograft rejection in pediatric kidney transplants.
    Puliyanda DP; Swinford R; Pizzo H; Garrison J; De Golovine AM; Jordan SC
    Pediatr Transplant; 2021 Mar; 25(2):e13850. PubMed ID: 33217125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Assessment of the Value of Donor-derived Cell-free DNA Surveillance in Patients With Preserved Kidney Allograft Function.
    Huang E; Haas M; Gillespie M; Sethi S; Peng A; Najjar R; Vo A; Jordan SC
    Transplantation; 2023 Jan; 107(1):274-282. PubMed ID: 35913057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real-World Analysis of Donor-Derived Cell-Free DNA-Based Surveillance Protocol.
    Akabas L; Bravo SA; Zhang Y; Simonelli A; Zuckerman WA; Richmond ME; Lytrivi ID
    Clin Transplant; 2024 Oct; 38(10):e15481. PubMed ID: 39412485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Performance of Donor-Derived Plasma Cell-Free DNA Fraction for Antibody-Mediated Rejection in Post Renal Transplant Recipients: A Prospective Observational Study.
    Zhang H; Zheng C; Li X; Fu Q; Li J; Su Q; Zeng L; Liu Z; Wang J; Huang H; Xu B; Ye M; Liu L; Wang C
    Front Immunol; 2020; 11():342. PubMed ID: 32184785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining donor-derived cell-free DNA and donor specific antibody testing as non-invasive biomarkers for rejection in kidney transplantation.
    Obrișcă B; Butiu M; Sibulesky L; Bakthavatsalam R; Smith KD; Gimferrer I; Warner P; Ismail G; Leca N
    Sci Rep; 2022 Sep; 12(1):15061. PubMed ID: 36064740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between dd-cfDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort.
    Sawinski DL; Mehta S; Alhamad T; Bromberg JS; Fischbach B; Aeschbacher T; Ghosh S; Shekhtman G; Dholakia S; Brennan DC; Poggio E; Bloom RD; Jordan SC
    Clin Transplant; 2021 Sep; 35(9):e14402. PubMed ID: 34184326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications.
    Akifova A; Budde K; Oellerich M; Beck J; Bornemann-Kolatzki K; Schütz E; Osmanodja B
    Transpl Int; 2024; 37():13239. PubMed ID: 39188271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol-based donor-derived cell-free DNA surveillance in kidney transplant recipients: A single-center experience.
    Nissaisorakarn P; Patel H; Amtul A; Pavlakis M
    Clin Nephrol; 2022 Aug; 98(2):65-74. PubMed ID: 35445660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition of Renal Patients Using AlloSure Into Community Kidney Care (TRACK): Protocol for Long-Term Allograft Surveillance in Renal Transplant Recipients.
    Dale BL; Bose S; Kuo S; Burns A; Daou P; Short J; Miles J
    JMIR Res Protoc; 2021 Mar; 10(3):e25941. PubMed ID: 33720033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.